Ischemia Care

Ischemia Care is a commercial-stage molecular diagnostics company that developed the first blood-based gene expression test for stroke. The company's proprietary ISCDx platform uses RNA expression and machine learning to differentiate between causes of stroke, such as cardioembolic (atrial fibrillation) and large artery atherosclerosis, helping clinicians personalize secondary prevention and reduce recurrent strokes. Headquartered in Oxford, Ohio, the company operates a CLIA-certified laboratory and has conducted the largest stroke biomarker trial to date (BASE). Their technology aims to address the 'cryptogenic' stroke gap, where the cause of stroke is unknown in nearly 40% of cases, leading to higher costs and poorer patient outcomes.